Hem › Levercancer (hepatocellulärt karcinom) › Pennsylvania › Pittsburgh
Kliniska studier för Levercancer (hepatocellulärt karcinom) i Pittsburgh, PA
15 studier för Levercancer (hepatocellulärt karcinom) söker deltagare vid platser i och runt Pittsburgh (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekryterarFas 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekryterarFas 1
- Exelixis Clinical Site #32, Pittsburgh
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
RekryterarFas 1/2
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RekryterarFas 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RekryterarFas 3
- Research Site, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekryterarFas 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekryterarFas 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Molecular Basis of Pediatric Liver Cancer
RekryterarObservationsstudie
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RekryterarFas 2
- Allegheny General Hospital, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RekryterarFas 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RekryterarFas 1
- Clinical Trial Site, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RekryterarFas 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RekryterarFas 2
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
RekryterarFas 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RekryterarFas 2
- UPMC Hillman Cancer Center, Pittsburgh
Levercancer (hepatocellulärt karcinom)-studier i andra städer
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Chicago, IL16 studier
- Philadelphia, PA16 studier
- San Francisco, CA14 studier
- Orange, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
Andra studier i Pittsburgh
- Icke-småcellig lungcancer48 studier
- Cancer (alla typer)41 studier
- Bröstcancer39 studier
- Kolorektal cancer32 studier
- Metastaserande cancer31 studier
- Melanom31 studier
- Äggstockscancer30 studier
- Endometriecancer23 studier
- Prostatacancer23 studier
- Lungcancer23 studier
- Plattenepitelcancer i huvud och hals22 studier
- Stroke22 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.